Inotuzumab Shows Promise for ALL in Real-World Study
TOPLINE:Inotuzumab ozogamicin (IO), an anti‐CD22 antibody conjugated with calicheamicin, was well tolerated and demonstrated an overall response rate of 74%...
Lawanda Stoval
Eisai: Update on the Co-Promotion of the Oral Antifungal Agent Nailin Capsules 100mg in Japan
TOKYO, Mar 5, 2025 - (JCN Newswire) - Sato Pharmaceutical Co., Ltd. and Eisai Co., Ltd. announced today that they...
